BICDL2

Across TCGA pan-cancer cohorts, BICDL2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of BICDL2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BICDL2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BICDL2 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

HNSC and LUAD are the cancer types where BICDL2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BICDL2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−1.748	<.001	11	view →
LUAD	Female	All	+0.501	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

BICDL2–HNSC

Open the HNSC breakdown →